{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:45:17Z","timestamp":1789753517833,"version":"4.0.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science and Technology Council, Taiwan","award":["NSTC 113-2314-B-075B-011 and NSTC 114-2314-B-075B-017"],"award-info":[{"award-number":["NSTC 113-2314-B-075B-011 and NSTC 114-2314-B-075B-017"]}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare, Taiwan","doi-asserted-by":"crossref","award":["11310"],"award-info":[{"award-number":["11310"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taoyuan General Hospital, Taiwan","award":["PTH114001, PTHTM114001, and PTH114002"],"award-info":[{"award-number":["PTH114001, PTHTM114001, and PTH114002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02770-x","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:26:38Z","timestamp":1772245598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"I-Ta","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thuy Tien","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"2770_CR1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Su\u00e1rez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888\u201398.","journal-title":"Lancet Oncol"},{"key":"2770_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T. KEYNOTE-564 Investigators. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683\u201394.","journal-title":"N Engl J Med"},{"key":"2770_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Ju\u00e1rez Soto \u00c1, Merseburger AS, \u00d6zg\u00fcro\u011flu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S. TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"2770_CR4","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"2770_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"2770_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"2770_CR7","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/cells9092051","volume":"9","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. Is there a role for immunotherapy in prostate cancer? Cells. 2020;9:2051.","journal-title":"Cells"},{"key":"2770_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"2770_CR9","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","volume":"300","author":"PL Weiden","year":"1979","unstructured":"Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068\u201373.","journal-title":"N Engl J Med"},{"key":"2770_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/cancers13061481","volume":"13","author":"P Wendel","year":"2021","unstructured":"Wendel P, Reindl LM, Bexte T, K\u00fcnnemeyer L, S\u00e4rchen V, Albinger N, Mackensen A, Rettinger E, Bopp T, Ullrich E. Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy. Cancers (Basel). 2021;13:1481.","journal-title":"Cancers (Basel)"},{"key":"2770_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"2770_CR12","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.3390\/jcm12196124","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med. 2023;12:6124.","journal-title":"J Clin Med"},{"key":"2770_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139\u201349.","journal-title":"J Exp Med"},{"key":"2770_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13046-021-02184-2","volume":"40","author":"A Sharma","year":"2021","unstructured":"Sharma A, Schmidt-Wolf IGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res. 2021;40:388.","journal-title":"J Exp Clin Cancer Res"},{"key":"2770_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2017.06.003","volume":"36","author":"E Cappuzzello","year":"2017","unstructured":"Cappuzzello E, Sommaggio R, Zanovello P, Rosato A. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine Growth Factor Rev. 2017;36:99\u2013105.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2770_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","volume":"153","author":"PH Lu","year":"1994","unstructured":"Lu PH, Negrin RS. A novel population of expanded human CD3\u2009+\u2009CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687\u201396.","journal-title":"J Immunol"},{"key":"2770_CR17","doi-asserted-by":"publisher","first-page":"e002475","DOI":"10.1136\/jitc-2021-002475","volume":"9","author":"A Dalla Piet\u00e0","year":"2021","unstructured":"Dalla Piet\u00e0 A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, Chieregato K, Mozzo V, Perbellini O, Tisi MC, Trentin L, Visco C, Ruggeri M, Sommaggio R, Rosato A. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. J Immunother Cancer. 2021;9:e002475.","journal-title":"J Immunother Cancer"},{"key":"2770_CR18","doi-asserted-by":"publisher","first-page":"e1199311","DOI":"10.1080\/2162402X.2016.1199311","volume":"5","author":"E Cappuzzello","year":"2016","unstructured":"Cappuzzello E, Tosi A, Zanovello P, Sommaggio R, Rosato A. Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 2016;5:e1199311.","journal-title":"Oncoimmunology"},{"key":"2770_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7150\/jca.2.363","volume":"2","author":"D Sangiolo","year":"2011","unstructured":"Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363\u20138.","journal-title":"J Cancer"},{"key":"2770_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/intimm\/dxn042","volume":"20","author":"D Sangiolo","year":"2008","unstructured":"Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008;20:841\u20138.","journal-title":"Int Immunol"},{"key":"2770_CR21","doi-asserted-by":"publisher","first-page":"1777046","DOI":"10.1080\/2162402X.2020.1777046","volume":"9","author":"R Sommaggio","year":"2020","unstructured":"Sommaggio R, Cappuzzello E, Dalla Piet\u00e0 A, Tosi A, Palmerini P, Carpanese D, Nicol\u00e8 L, Rosato A. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. Oncoimmunology. 2020;9:1777046.","journal-title":"Oncoimmunology"},{"key":"2770_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12964-022-00836-0","volume":"20","author":"F Fayyaz","year":"2022","unstructured":"Fayyaz F, Yazdanpanah N, Rezaei N. Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer. Cell Commun Signal. 2022;20:41.","journal-title":"Cell Commun Signal"},{"key":"2770_CR23","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1038\/s41598-020-63634-z","volume":"10","author":"S Capellero","year":"2020","unstructured":"Capellero S, Erriquez J, Melano C, Mesiano G, Genta S, Pisacane A, Mittica G, Ghisoni E, Olivero M, Di Renzo MF, Aglietta M, Sangiolo D, Valabrega G. Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer. Sci Rep. 2020;10:6478.","journal-title":"Sci Rep"},{"key":"2770_CR24","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/ijc.28775","volume":"136","author":"A L\u00f3pez-Soto","year":"2015","unstructured":"L\u00f3pez-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S. NKG2D signaling in cancer immunosurveillance. Int J Cancer. 2015;136:1741\u201350.","journal-title":"Int J Cancer"},{"key":"2770_CR25","doi-asserted-by":"publisher","first-page":"731767","DOI":"10.3389\/fimmu.2021.731767","volume":"12","author":"X Wu","year":"2021","unstructured":"Wu X, Sharma A, Oldenburg J, Weiher H, Essler M, Skowasch D, Schmidt-Wolf IGH. NKG2D engagement alone is sufficient to activate cytokine-induced killer cells while 2B4 only provides limited coactivation. Front Immunol. 2021;12:731767.","journal-title":"Front Immunol"},{"key":"2770_CR26","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","volume":"103","author":"MR Verneris","year":"2004","unstructured":"Verneris MR, Karimi M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8\u2009+\u2009T cells. Blood. 2004;103:3065\u201372.","journal-title":"Blood"},{"key":"2770_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/sj.cdd.4400373","volume":"5","author":"JA Trapani","year":"1998","unstructured":"Trapani JA, Jans P, Smyth MJ, Froelich CJ, Williams EA, Sutton VR, Jans DA. Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Differ. 1998;5:488\u201396.","journal-title":"Cell Death Differ"},{"key":"2770_CR28","doi-asserted-by":"publisher","first-page":"896228","DOI":"10.3389\/fimmu.2022.896228","volume":"13","author":"A Ram\u00edrez-Labrada","year":"2022","unstructured":"Ram\u00edrez-Labrada A, Pesini C, Santiago L, Hidalgo S, Calvo-P\u00e9rez A, O\u00f1ate C, Andr\u00e9s-Tovar A, Garz\u00f3n-Titua\u00f1a M, Uranga-Murillo I, Arias MA, Galvez EM, Pardo J. All about (NK cell-mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity. Front Immunol. 2022;13:896228.","journal-title":"Front Immunol"},{"key":"2770_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3390\/cancers14061436","volume":"14","author":"E Tibbs","year":"2022","unstructured":"Tibbs E, Cao X. Emerging canonical and non-canonical roles of Granzyme B in health and disease. Cancers (Basel). 2022;14:1436.","journal-title":"Cancers (Basel)"},{"key":"2770_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12865-023-00552-5","volume":"24","author":"YY Lee","year":"2023","unstructured":"Lee YY, Luo SC, Lee CH, Tang CL, Shen CC, Cheng WY, Yang YC, Yang MY, Yen CM. Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing. BMC Immunol. 2023;24:14.","journal-title":"BMC Immunol"},{"key":"2770_CR31","doi-asserted-by":"publisher","first-page":"102665","DOI":"10.1016\/j.ctrv.2023.102665","volume":"122","author":"CM Ying Li","year":"2024","unstructured":"Ying Li CM, Li R, Drew P, Price T, Smith E, Maddern GJ, Tomita Y, Fenix K. Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges. Cancer Treat Rev. 2024;122:102665.","journal-title":"Cancer Treat Rev"},{"key":"2770_CR32","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.4049\/jimmunol.1601004","volume":"198","author":"D Urlaub","year":"2017","unstructured":"Urlaub D, H\u00f6fer K, M\u00fcller ML, Watzl C. LFA-1 activation in NK cells and their subsets: influence of receptors, maturation, and cytokine stimulation. J Immunol. 2017;198:1944\u201351.","journal-title":"J Immunol"},{"key":"2770_CR33","first-page":"123","volume":"20","author":"Y Zou","year":"2020","unstructured":"Zou Y, Liang J, Li D, Fang J, Wang L, Wang J, Zhang J, Guo Q, Yan X, Tang H. Application of the chemokine-chemokine receptor axis increases the tumor-targeted migration ability of cytokine-induced killer cells in patients with colorectal cancer. Oncol Lett. 2020;20:123\u201334.","journal-title":"Oncol Lett"},{"key":"2770_CR34","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/cancers11070944","volume":"11","author":"ID Rosero","year":"2019","unstructured":"Rosero ID, Ram\u00edrez-V\u00e9lez R, Lucia A, Mart\u00ednez-Velilla N, Santos-Lozano A, Valenzuela PL, Morilla I, Izquierdo M. Systematic review and meta-analysis of randomized, controlled trials on preoperative physical exercise interventions in patients with non-small-cell lung cancer. Cancers (Basel). 2019;11:944.","journal-title":"Cancers (Basel)"},{"key":"2770_CR35","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.asjsur.2022.12.049","volume":"46","author":"H Guo","year":"2023","unstructured":"Guo H, Meng Y, Peng J, Yang X. Post-operative adjuvant immunotherapy with cytokine-induced killer and dendritic cells for hepatocellular carcinoma: A systematic review and meta-analysis. Asian J Surg. 2023;46:2433\u20136.","journal-title":"Asian J Surg"},{"key":"2770_CR36","doi-asserted-by":"publisher","first-page":"e006764","DOI":"10.1136\/jitc-2023-006764","volume":"11","author":"CMY Li","year":"2023","unstructured":"Li CMY, Tomita Y, Dhakal B, Li R, Li J, Drew P, Price T, Smith E, Maddern GJ, Fenix KA. Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. J Immunother Cancer. 2023;11:e006764.","journal-title":"J Immunother Cancer"},{"key":"2770_CR37","doi-asserted-by":"publisher","first-page":"1476644","DOI":"10.3389\/fimmu.2025.1476644","volume":"16","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Qiu J, Ye N, Xu Y. Current status of cytokine-induced killer cells and combination regimens in breast cancer. Front Immunol. 2025;16:1476644.","journal-title":"Front Immunol"},{"key":"2770_CR38","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s10147-020-01750-6","volume":"25","author":"G Hu","year":"2020","unstructured":"Hu G, Zhong K, Wang S, Wang S, Ding Q, Xu F, Chen W, Cheng P, Huang L. Cellular immunotherapy plus chemotherapy ameliorates survival in gastric cancer patients: a meta-analysis. Int J Clin Oncol. 2020;25:1747\u201356.","journal-title":"Int J Clin Oncol"},{"key":"2770_CR39","doi-asserted-by":"publisher","first-page":"e24519","DOI":"10.1097\/MD.0000000000024519","volume":"100","author":"X Yuan","year":"2021","unstructured":"Yuan X, Zhang AZ, Ren YL, Wang XL, Jiang CH, Yang L, Liu CX, Liang WH, Pang LJ, Gu WY, Li F, Hu JM. Cytokine-induced killer cells\/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis. Med (Baltim). 2021;100:e24519.","journal-title":"Med (Baltim)"},{"key":"2770_CR40","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.7150\/jca.25790","volume":"9","author":"JJ Zhao","year":"2018","unstructured":"Zhao JJ, Zhou S, Chen CL, Zhang HX, Zhou ZQ, Wu ZR, Liu Y, Pan QZ, Zhu Q, Tang Y, Xia JC, Weng DS. Clinical effect of adjuvant cytokine-induced killer cells immunotherapy in patients with stage II-IVB nasopharyngeal carcinoma after chemoradiotherapy: A propensity score analysis. J Cancer. 2018;9:4204\u201314.","journal-title":"J Cancer"},{"key":"2770_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13046-024-02973-5","volume":"43","author":"M Regmi","year":"2024","unstructured":"Regmi M, Wang Y, Liu W, Dai Y, Liu S, Ma K, Lin G, Yang J, Liu H, Wu J, Yang C. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review. J Exp Clin Cancer Res. 2024;43:47.","journal-title":"J Exp Clin Cancer Res"},{"key":"2770_CR42","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5:1411\u201320.","journal-title":"JAMA Oncol"},{"key":"2770_CR43","doi-asserted-by":"publisher","first-page":"5709104","DOI":"10.1155\/2021\/5709104","volume":"2021","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wang RQ, Zhong YM, Meng MY, Zhao YY, Yang LR, Li L, Hou ZL. Efficacy of enhanced cytokine-induced killer cells as an adjuvant immunotherapy for renal cell carcinoma: preclinical and clinical studies. J Healthc Eng. 2021;2021:5709104.","journal-title":"J Healthc Eng"},{"key":"2770_CR44","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-11-2442","volume":"18","author":"L Liu","year":"2012","unstructured":"Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18:1751\u20139.","journal-title":"Clin Cancer Res"},{"key":"2770_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.canlet.2015.03.043","volume":"362","author":"X Zhao","year":"2015","unstructured":"Zhao X, Zhang Z, Li H, Huang J, Yang S, Xie T, Huang L, Yue D, Xu L, Wang L, Zhang W, Zhang Y. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett. 2015;362:192\u20138.","journal-title":"Cancer Lett"},{"key":"2770_CR46","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00002371-200111000-00007","volume":"24","author":"A M\u00e4rten","year":"2001","unstructured":"M\u00e4rten A, Ziske C, Sch\u00f6ttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von R\u00fccker A, Sauerbruch T, Schmidt-Wolf IG. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001;24:502\u201310.","journal-title":"J Immunother"},{"key":"2770_CR47","first-page":"3771","volume":"125","author":"HL Zhan","year":"2012","unstructured":"Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou XF, Qiu JG. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl). 2012;125:3771\u20137.","journal-title":"Chin Med J (Engl)"},{"key":"2770_CR48","doi-asserted-by":"publisher","first-page":"195691","DOI":"10.1155\/2013\/195691","volume":"2013","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Wang J, Wang Y, Lu XC, Fan H, Liu Y, Zhang Y, Feng KC, Zhang WY, Chen MX, Fu X, Han WD. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clin Dev Immunol. 2013;2013:195691.","journal-title":"Clin Dev Immunol"},{"key":"2770_CR49","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/cancers14061406","volume":"14","author":"L Kasherman","year":"2022","unstructured":"Kasherman L, Siu DHW, Woodford R, Harris CA. Angiogenesis inhibitors and immunomodulation in renal cell cancers: the past, present, and future. Cancers (Basel). 2022;14:1406.","journal-title":"Cancers (Basel)"},{"key":"2770_CR50","first-page":"505","volume":"20","author":"K Zheng","year":"2015","unstructured":"Zheng K, Tan JM, Wu WZ, Qiu YM, Zhang H, Xu TZ, Sun XH, Zhuo WL, Wang D, Zhang JP. Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery. J BUON. 2015;20:505\u201313.","journal-title":"J BUON"},{"key":"2770_CR51","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2217\/imt.14.41","volume":"6","author":"ZX Wang","year":"2014","unstructured":"Wang ZX, Li JL, Cao JX, Liu YS, Li D, Zhang XY, Wang M, Wu M, Xu BL, Liu JL, Wang HB. Cytokine-induced killer cells in the treatment of patients with renal cell carcinoma: a pooled meta-analysis. Immunotherapy. 2014;6:787\u201395.","journal-title":"Immunotherapy"},{"key":"2770_CR52","doi-asserted-by":"publisher","first-page":"S427","DOI":"10.4103\/0973-1482.180609","volume":"14","author":"HX Mai","year":"2018","unstructured":"Mai HX, Mei GH, Zhao FL, Li BT, Tang YY, Zhang B, Xu XJ, Chen LJ. Retrospective analysis on the efficacy of sunitinib\/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy. J Cancer Res Ther. 2018;14:S427\u201332.","journal-title":"J Cancer Res Ther"},{"key":"2770_CR53","doi-asserted-by":"publisher","first-page":"e1257","DOI":"10.1002\/cti2.1257","volume":"10","author":"MJ Song","year":"2021","unstructured":"Song MJ, Pan QZ, Ding Y, Zeng J, Dong P, Zhao JJ, Tang Y, Li J, Zhang Z, He J, Yang J, Huang Y, Peng R, Wang QJ, Gu JM, He J, Li YQ, Chen SP, Huang R, Zhou ZQ, Yang C, Han Y, Chen H, Liu H, Xia S, Wan Y, Weng DS, Xia L, Zhou FJ, Xia JC. The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. Clin Transl Immunol. 2021;10:e1257.","journal-title":"Clin Transl Immunol"},{"key":"2770_CR54","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.21037\/tau-21-406","volume":"10","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Xiong L, Wu Z, Liu H, Ning K, Peng Y, Yu C, Ding Y, Weng D, Xia J, Jiang L, Guo S, Han H, Zhou F, Dong P. Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma. Transl Androl Urol. 2021;10:2091\u2013102.","journal-title":"Transl Androl Urol"},{"key":"2770_CR55","doi-asserted-by":"publisher","first-page":"779248","DOI":"10.3389\/fimmu.2021.779248","volume":"12","author":"L Zhao","year":"2022","unstructured":"Zhao L, Li T, Song Y, Yang Y, Ma B, Zhang Y, Shang Y, Xu B, Guo J, Qin P, Han L, Fu X, Lin H, Liu L, Ren X, Wang Z, Gao Q. High complete response rate in patients with metastatic renal cell carcinoma receiving autologous cytokine-induced killer cell therapy plus anti-programmed death-1 agent: A single-center study. Front Immunol. 2022;12:779248.","journal-title":"Front Immunol"},{"key":"2770_CR56","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/14712598.2024.2418321","volume":"24","author":"N Chaoul","year":"2024","unstructured":"Chaoul N, Lauricella E, Giglio A, D\u2019Angelo G, Ganini C, Cives M, Porta C. The future of cellular therapy for the treatment of renal cell carcinoma. Expert Opin Biol Ther. 2024;24:1245\u201359.","journal-title":"Expert Opin Biol Ther"},{"key":"2770_CR57","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/cancers16061209","volume":"16","author":"A Hwang","year":"2024","unstructured":"Hwang A, Mehra V, Chhetri J, Ali S, Tran M, Roddie C. Current treatment options for renal cell carcinoma: focus on cell-based immunotherapy. Cancers (Basel). 2024;16:1209.","journal-title":"Cancers (Basel)"},{"key":"2770_CR58","doi-asserted-by":"publisher","first-page":"1582887","DOI":"10.3389\/fimmu.2025.1582887","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang B, Xiang Y, Liu X, Pan X, Peng L, Ma J. Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions. Front Immunol. 2025;16:1582887.","journal-title":"Front Immunol"},{"key":"2770_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-023-01911-x","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Suarez ER, Kastrunes G, de Campos NSP, Abbas R, Pivetta RS, Murugan N, Chalbatani GM, D\u2019Andrea V, Marasco WA. Evolution of cell therapy for renal cell carcinoma. Mol Cancer. 2024;23:8.","journal-title":"Mol Cancer"},{"key":"2770_CR60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. JAMA Oncol. 2024;10:807\u201320.","journal-title":"JAMA Oncol"},{"key":"2770_CR61","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/JU.0000000000001578","volume":"205","author":"TJ Wilt","year":"2021","unstructured":"Wilt TJ, Ullman KE, Linskens EJ, MacDonald R, Brasure M, Ester E, Nelson VA, Saha J, Sultan S, Dahm P. Therapies for clinically localized prostate cancer: a comparative effectiveness review. J Urol. 2021;205:967\u201376.","journal-title":"J Urol"},{"key":"2770_CR62","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol. 2023;9:635\u201345.","journal-title":"JAMA Oncol"},{"key":"2770_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","volume":"87","author":"E Francini","year":"2025","unstructured":"Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, Mateo J, Rathkopf D, Saad F, Tombal B. Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review. Eur Urol. 2025;87:29\u201346.","journal-title":"Eur Urol"},{"key":"2770_CR64","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520\u20136.","journal-title":"Clin Cancer Res"},{"key":"2770_CR65","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753\u20138.","journal-title":"Clin Cancer Res"},{"key":"2770_CR66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13287-020-01634-6","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Li Y, Wang Y, Wu D, Lau AHY, Zhao P, Zou C, Dai Y, Chan FL. Targeting prostate cancer stem-like cells by an immunotherapeutic platform based on immunogenic peptide-sensitized dendritic cells-cytokine-induced killer cells. Stem Cell Res Ther. 2020;11:123.","journal-title":"Stem Cell Res Ther"},{"key":"2770_CR67","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.21873\/anticanres.15829","volume":"42","author":"YC Shen","year":"2022","unstructured":"Shen YC, Shih HJ, Lin CC, Huang SH, Wu SC, Hsiao CH, Chiu SC, Cho DY, Chang CP, Pan Y, Shih PH. Synergistic benefit of adoptive T cells in combination with chemoradiotherapy against metastatic prostate cancer cells. Anticancer Res. 2022;42:3427\u201334.","journal-title":"Anticancer Res"},{"key":"2770_CR68","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s12013-024-01569-2","volume":"83","author":"Y Li","year":"2025","unstructured":"Li Y, Chen S, Liu S. Immune effect of co-culture of dendritic cells and cytokine-induced killer cells on prostate cancer cells. Cell Biochem Biophys. 2025;83:1593\u2013604.","journal-title":"Cell Biochem Biophys"},{"key":"2770_CR69","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/jcmm.17923","volume":"27","author":"T Pungsrinont","year":"2023","unstructured":"Pungsrinont T, Schneider MA, Baniahmad A. Androgen receptor agonist and antagonist reduce response of cytokine-induced killer cells on prostate cancer cells. J Cell Mol Med. 2023;27:2970\u201382.","journal-title":"J Cell Mol Med"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02770-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02770-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02770-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:20:44Z","timestamp":1775571644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02770-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02770-x","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}